154 related articles for article (PubMed ID: 31782901)
1. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
[TBL] [Abstract][Full Text] [Related]
2. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
[TBL] [Abstract][Full Text] [Related]
3. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.
Hvas AM; Sørensen HT; Norengaard L; Christiansen K; Ingerslev J; Sørensen B
J Thromb Haemost; 2007 Dec; 5(12):2408-14. PubMed ID: 18034766
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
Dai L; Bevan D; Rangarajan S; Sørensen B; Mitchell M
Haemophilia; 2011 Sep; 17(5):e944-8. PubMed ID: 21371192
[TBL] [Abstract][Full Text] [Related]
5. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
[TBL] [Abstract][Full Text] [Related]
6. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Rea CJ; Foley JH; Bevan DH; Sørensen B
Ann Hematol; 2014 Apr; 93(4):683-92. PubMed ID: 24193375
[TBL] [Abstract][Full Text] [Related]
7. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.
Valke LLFG; Bukkems LH; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Mathôt RAA; van Heerde WL; Schols SEM
J Thromb Haemost; 2020 Dec; 18(12):3222-3231. PubMed ID: 32979031
[TBL] [Abstract][Full Text] [Related]
10. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
12. The combination of emicizumab and recombinant factor VIII in plasma: Which assays can we use for accurate measurement?
Bowyer AE; Maclean RM; Kitchen S
Int J Lab Hematol; 2023 Jun; 45(3):368-376. PubMed ID: 36710421
[TBL] [Abstract][Full Text] [Related]
13. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
15. Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis.
Bukkems LH; Jönsson S; Cnossen MH; Karlsson MO; Mathôt RAA;
CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):706-718. PubMed ID: 36965157
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
[TBL] [Abstract][Full Text] [Related]
17. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
19. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
20. Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.
Huang ZY; Huang Q; Zeng HJ; Ma J; Shen B; Zhou ZK; Pei FX
BMC Musculoskelet Disord; 2019 Sep; 20(1):402. PubMed ID: 31481049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
